Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 1457 • 2018 ACR/ARHP Annual Meeting
Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
Peter M. ten Klooster^1,2, Laura M.M. Steunebrink³, Letty Versteeg⁴, Inmaculada de la Torre⁵, Francesco de Leonardis⁶, Walid Fakhouri⁶, Liliana Zaremba-Pechmann⁶ and Mart van de Laar^1,3, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ³Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁴Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁵Eli Lilly and Company, Madrid, Spain, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Recent studies suggested a disconnect between disease activity and radiographic damage in rheumatoid arthritis (RA) patients treated with more aggressive treatment (1). Therefore, the…
Abstract Number: 1483 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Features of Seronegative and Seropositive Early Rheumatoid Arthritis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients
Giampaolo Giacovelli, Beatrice Barbetta, Cristina Vitalini, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: Rheumatoid arthritis patients positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (ACPA) are considered to manifest an aggressive disease course compared with…
Abstract Number: 1485 • 2018 ACR/ARHP Annual Meeting
Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia
Malin C Erlandsson^1,2, Minna Turkkila³, Rille Pullerits^2,3,4 and Maria I Bokarewa^2,3, ¹Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, ²Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Department of Rheumatology, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, ⁴Department of Clinical immunology and transfusion medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
Background/Purpose: Early recognition of rheumatoid arthritis (RA) is believed to be the key to successful treatment of this disease. Symptoms of arthralgia often predate development…
Abstract Number: 1486 • 2018 ACR/ARHP Annual Meeting
Incidence of Subclinical Signs of Inflammation in Patients with New Onset of Non-Specific Musculoskeletal Symptoms and Anti-Citrullinated Peptide Positivity: First Interims Analysis of the Panora Trial
Michaela Koehm^1,2, Ulf Henkemeier^2,3, Tanja Rossmanith², Stephanie Dauth², Timm Oberwahrenbrock², Ann Christina Foldenauer², Karola Mergenthal⁴, Harald Burkhardt^2,3,5 and Frank Behrens^2,3,5, ¹Division of Rheumatology Goethe-University Frankfurt, Frankfurt/Main, Germany, ²Fraunhofer IME Branch for Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ³Centre of Innovative Diagnostics and Therapeutics Rheumatology / Immunology at University Hospital Goethe-University Frankfurt, Frankfurt, Germany, ⁴Institute for General Practice Goethe-University, Frankfurt, Germany, ⁵Division of Rheumatology Goethe-University Frankfurt, Frankfurt, Germany
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory joint disease affecting approx. 1% of the adult population of Northern Europe and North America. Strategies for…
Abstract Number: 1488 • 2018 ACR/ARHP Annual Meeting
Identification of Joint Locations That Are Poor Prognostic in an Early Seropositive Erosive RA Cohort
Patrick Durez¹, Sofie Robert², Alexandra Thiry³ and Harris A Ahmad³, ¹Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Bristol-Myers Squibb, Braine L’Alleud, Belgium, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Patients (pts) with early RA often present with multiple and different areas of joint involvement. While the ACR and EULAR guidelines specify high disease…
Abstract Number: 72 • 2018 ACR/ARHP Annual Meeting
Altered Serologic Responses to Epstein Barr Virus Precede Clinical Disease Development in Rheumatoid Arthritis
Heather M. Berens¹, Elizabeth A. Bemis², M. Kristen Demoruelle¹, John B. Harley³, Judith A. James⁴, Jess Edison⁵, Kevin D. Deane¹, Jill M. Norris⁶ and V. Michael Holers¹, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Division of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ⁶Department of Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: EBV infects B cells and is associated with several autoimmune diseases, including RA. Prior studies have shown that patients with active classified RA…
Abstract Number: 1492 • 2018 ACR/ARHP Annual Meeting
Methotrexate Response in Early Rheumatoid Arthritis Predicted Using a Somamer Proteomic Assay
Carol Hitchon¹, Victor Spicer¹, Nathalie Carrier², Ang Gao¹, Hani El-Gabalawy¹, John Wilkins¹ and Gilles Boire³, ¹University of Manitoba, Winnipeg, MB, Canada, ²Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ³Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Available clinical tools do not adequately identify treatment non-responders in early rheumatoid arthritis (RA) leading to delayed disease control. Tools informed by molecular phenotype…
Abstract Number: 310 • 2018 ACR/ARHP Annual Meeting
The Trajectory of Grade 1 Erosions in the Feet of Patients with Early RA
Mary-Clair Yelovich¹, Hanyan Zou¹, Siobhan Deshauer¹, Saara Totterman², Karen A. Beattie³ and Maggie Larche⁴, ¹McMaster University, Hamilton, ON, Canada, ²Qmetrics Technologies, Pittsford, NY, ³Medicine, McMaster University, Hamilton, ON, Canada, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: The identification of erosions plays a critical role in the management of RA, as the presence of erosions denotes more aggressive disease requiring more…
Abstract Number: 1493 • 2018 ACR/ARHP Annual Meeting
Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis
Gabriela Gonzalez and Juan Molina, Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: in rheumatoid arthritis (RA) patients the disease outcome has an unpredictable course and may differ even with an early diagnosis and treatment. Low disease…
Abstract Number: 313 • 2018 ACR/ARHP Annual Meeting
Do Musculoskeletal Ultrasound and Magnetic Resonance Imaging Identify Synovitis and Tenosynovitis at the Same Joints and Tendons? – a Comparative Study in Patients Presenting with Early Arthritis and Clinically Suspect Arthralgia
Aleid C. Boer¹, Sarah Ohrndorf², Debbie M. Boeters¹, Robin M ten Brinck¹, Gerd R. Burmester², Marion Kortekaas¹ and Annette H.M. van der Helm-van Mil^1,3, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: In the diagnostic process of RA, the use of advanced imaging techniques like musculoskeletal ultrasound (US) and magnetic resonance imaging (MRI) has been recommended.…
Abstract Number: 1934 • 2018 ACR/ARHP Annual Meeting
microRNA Targeting IL-33 Gene As Biomarker to Predict Subclinical Atherosclerosis in Patients with Early Rheumatoid Arthritis
Isaac T. Cheng¹, Qing Shang², Jiayun Shen³, Martin Li³, Queenie Mak², Kitty Y Kwok⁴, Isaac CW Yim⁵, Edmund Kwok Ming Li², Priscilla Wong¹, Ronald ML Yip⁶, Steve H Pang⁶ and Lai-Shan Tam⁷, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁵Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ⁶Department of Medicine, Kwong Wah Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong
Background/Purpose: Patients with RA had increased risk of cardiovascular disease (CVD). Interleukin 33 (IL-33) plays an important role in pathogenesis of RA and development of…
Abstract Number: 533 • 2018 ACR/ARHP Annual Meeting
Association between Inflammation and Changes in Kidney Function in Patients with Early Rheumatoid Arthritis
Ganna Prytkova¹, Dmytro Rekalov² and Daryna Nikitina¹, ¹Rheumatology, Zaporizhzhya Regional Clinical Hospital, Zaporizhzhya, Ukraine, ²Department of Internal Diseases, Zaporizhzhya Regional Clinical Hospital, Zaporizhzhya, Ukraine
Background/Purpose: One of the most severe visceral manifestations of RA is nephropathy. The key symptoms of renal dysfunction (RD) are microalbuminuria (MA), β-2-microglobulinuria (β-2M), reduced…
Abstract Number: 2505 • 2018 ACR/ARHP Annual Meeting
Sociodemographic Factors Are Predictors of Poorer Clinical Outcome Trajectories in Early Rheumatoid Arthritis: Results from the Singapore Early Arthritis Cohort
Yuhan Zou¹, Peter P.M. Cheung^2,3, Lay Kheng Teoh⁴ and Manjari Lahiri^2,3, ¹Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Division of Rheumatology, University Medicine Cluster, National University Hospital, Singapore, Singapore, Singapore, ³Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁴National University Hospital, Division of Rheumatology, University Medicine Cluster, Singapore, Singapore
Background/Purpose: Variable outcomes in early rheumatoid arthritis (ERA) may be explained by heterogeneous latent disease activity trajectories, the predictors of which are not well defined.…
Abstract Number: 563 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Abatacept in Combination with MTX in Early, MTX-Naïve, Anti-Citrullinated Protein Antibody–Positive Patients with RA: Primary and 1-Year Results from a Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka², Vivian P. Bykerk³, Tom W.J. Huizinga⁴, Gustavo Citera⁵, Marleen Nys⁶, Sean E. Connolly⁷, Alyssa Johnsen⁷ and Roy Fleischmann⁸, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Hospital for Special Surgery, New York, NY, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁶Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In patients (pts) with early (disease duration ≤24 months [mths]), MTX-naïve RA and poor prognostic factors including anti-citrullinated protein antibody (ACPA) positivity (+), abatacept…
Abstract Number: 2845 • 2018 ACR/ARHP Annual Meeting
A Close Relationship between a Novel Visceral Adiposity Index and Bone Microstructure in Female Early Rheumatoid Arthritis Patients: A 1-Year Follow-up Study By HR-pQCT
Jiang Yue^1,2, Priscilla Wong¹, James F Griffith³, Jiankun XU⁴, Fan XIAO⁵, Dongze Wu^1,2, Edmund Li¹, Lydia Ho Pui Tam⁶, Martin Li⁷, Tena K. Li¹, Tracy Y. Zhu⁸, Vivian W. Hung⁸, Ling Qin⁹ and Lai-Shan Tam¹⁰, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ⁴Department of Orthopedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁵Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁶Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁷Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁸Bone Quality and Health Centre of the Department of Orthopedics & Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ⁹Bone Quality and Health Centre of the Department of Orthopaedics and Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, hongkong, Hong Kong, ¹⁰Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong
Background/Purpose: Background: Obesity has been traditionally considered to protect the skeleton against osteoporosis and fracture. Recently, body fat, specifically visceral adipose tissue (VAT), has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].